Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,861 to 4,880 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| ABCWY Group vs ACWY Group: Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs) | 96 of 626 93 of 621 | 0.4 points -3.6 to 4.3 | 1,247 | NCT04707391 Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine |
| ABCWY Group vs ACWY Group: deaths from any cause | 1 of 626 1 of 621 | -0.0 points -0.8 to 0.8 | 1,247 | NCT04707391 Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine |
| ABCWY Group vs ACWY Group: serious adverse events | 18 of 626 7 of 621 | 1.7 points 0.2 to 3.5 | 1,247 | NCT04707391 Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine |
| Sita/Met FDC vs Metformin: serious adverse events | 28 of 625 38 of 621 | -1.6 points -4.2 to 0.9 | 1,246 | NCT00482729 MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED) |
| Resources for Services RS vs Community Engagement and Planning CEP: deaths from any cause | 4 of 606 4 of 640 | 0.0 points -1.0 to 1.1 | 1,246 | NCT01699789 Community Partners in Care is a Research Project Funded by the National Institutes of Health |
| qHPV Vaccine in Base Study vs qHPV Vaccine in Extension Study: Number of Participants Reporting SAEs Related to Study Vaccine or to a Study Procedure in the Long-term Follow-up | 0 of 821 1 of 424 | -0.2 points -1.3 to 0.3 | 1,245 | NCT00092547 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) |
| Cervarix Group vs Havrix Group: serious adverse events | 33 of 626 5 of 619 | 4.5 points 2.6 to 6.6 | 1,245 | NCT00316706 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine |
| Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs. | 3 of 360 15 of 885 | -0.9 points -2.1 to 0.9 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Male vs Female: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender. | 7 of 458 11 of 787 | 0.1 points -1.2 to 1.8 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Without Hypertension vs With Hypertension: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension. | 0 of 8 18 of 1,237 | -1.5 points -2.3 to 31.0 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Without Hypercholesterolemia vs With Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia. | 0 of 18 18 of 1,227 | -1.5 points -2.3 to 16.1 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Without Complications vs With Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications. | 5 of 568 13 of 677 | -1.0 points -2.5 to 0.4 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| <65 Years vs >=65 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age. | 5 of 377 13 of 868 | -0.2 points -1.5 to 1.7 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Without Angina Pectoris vs With Angina Pectoris: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris. | 18 of 1,062 0 of 183 | 1.7 points -0.5 to 2.7 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Without Familial Hypercholesterolemia vs With Familial Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia. | 18 of 1,231 0 of 14 | 1.5 points -20.1 to 2.3 | 1,245 | NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
| Ramucirumab and Docetaxel vs Placebo and Docetaxel: serious adverse events | 284 of 627 281 of 618 | -0.2 points -5.7 to 5.3 | 1,245 | NCT01168973 A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy |
| Standard Care + Nicotine Replacement Therapy (NRT) vs Standard Care: deaths from any cause | 1 of 593 3 of 652 | -0.3 points -1.2 to 0.5 | 1,245 | NCT02096029 Tobacco Intervention in Primary Care Treatment Opportunities for Providers |
| Standard Care + Nicotine Replacement Therapy (NRT) vs Standard Care: serious adverse events | 9 of 593 20 of 652 | -1.5 points -3.3 to 0.2 | 1,245 | NCT02096029 Tobacco Intervention in Primary Care Treatment Opportunities for Providers |
| BE1116 vs Placebo: serious adverse events | 203 of 618 168 of 627 | 6.1 points 1.0 to 11.1 | 1,245 | NCT05568888 Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) |
| Palbociclib vs Placebo: deaths from any cause | 63 of 633 67 of 611 | -1.0 points -4.5 to 2.4 | 1,244 | NCT01864746 A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery |
Code
curl "https://conductscience.org/api/comparisons/v1?page=244"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=244
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04707391-4cf64514",
"title": "ABCWY Group vs ACWY Group: Number of Participants With Any Unsolicited Adverse Events (AEs) (Including All Serious Adverse Events [SAEs], AEs Leading to Withdrawal, AEs of Special Interest [AESIs] and Medically Attended AEs)",
"summary": "96 of 626 against 93 of 621; risk difference 0.4 points, 95% interval -3.6 to 4.3; NCT04707391, Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine",
"record": "/library/comparisons/NCT04707391-4cf64514",
"nct_id": "NCT04707391",
"kind": "outcome",
"participants": 1247,
"risk_difference": {
"value": 0.0035961784815792264,
"lower": -0.036334236346420745,
"upper": 0.043488475203239424
},
"group_1": "96 of 626",
"group_2": "93 of 621",
"difference": "0.4 points",
"interval": "-3.6 to 4.3",
"trial_title": "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine"
},
{
"id": "NCT04707391-deaths",
"title": "ABCWY Group vs ACWY Group: deaths from any cause",
"summary": "1 of 626 against 1 of 621; risk difference -0.0 points, 95% interval -0.8 to 0.8; NCT04707391, Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine",
"record": "/library/comparisons/NCT04707391-deaths",
"nct_id": "NCT04707391",
"kind": "deaths",
"participants": 1247,
"risk_difference": {
"value": -0.000012861868675176141,
"lower": -0.007582118993223607,
"upper": 0.00750008163523229
},
"group_1": "1 of 626",
"group_2": "1 of 621",
"difference": "-0.0 points",
"interval": "-0.8 to 0.8",
"trial_title": "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=245",
"request_id": "snqCn6_c-wdgWH4i"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant